ResMed Inc. (RMD), the San Diego-based global leader in sleep apnea devices and cloud-connected respiratory care platforms, has seen its shares decline roughly 28% over the past twelve months — from levels above $270 to a recent close of $195.27. That slide has pushed the stock toward its cheapest valuation in more than a decade, intensifying the debate about whether a recovery toward $250 is realistic.
The $250 level matters for several reasons. It sits near the current Wall Street consensus price target, which averages between $247 and $267 depending on the data source. It also represents a psychologically significant round number and would mark a convincing break back above the 200-day moving average, currently situated around $229. For a stock that hit an all-time high of $292.36 in August 2025, reclaiming $250 would signal that the worst of the selloff may be over.
ResMed operates in a global duopoly with Philips, together controlling an estimated 80% of the obstructive sleep apnea (OSA) device market across more than 140 countries. The company develops CPAP and bilevel flow generators, masks, and software-as-a-service platforms used by patients, clinicians, and healthcare providers. Approximately two-thirds of revenue comes from the Americas.
The structural growth story remains compelling. An estimated 900 million people worldwide suffer from sleep apnea, yet fewer than 20% have been diagnosed or treated in the United States alone. Rising awareness — partly driven by wearable technologies such as the Apple Watch detecting sleep irregularities — continues to expand the diagnosis funnel. ResMed's most recent quarterly results, reported in April 2026, showed revenue growing 11% year-over-year to $1.43 billion, with non-GAAP diluted EPS (earnings per share) climbing 21% to $2.86.
Several factors could propel RMD back toward $250. Gross margins have expanded significantly — reaching 62.2% in the most recent quarter, up 290 basis points year-over-year — thanks to component cost improvements, manufacturing efficiencies, and a favorable product mix shift toward higher-margin masks. Management has guided for continued margin accretion through 2030.
The GLP-1 narrative is also evolving. Contrary to early fears that weight-loss drugs would shrink the addressable CPAP market, ResMed's own real-world data shows that patients prescribed GLP-1 medications are actually more likely to initiate and adhere to CPAP therapy — likely because they represent a more health-motivated cohort. Several analysts, including those at Morningstar, have described GLP-1 concerns as overblown.
Additionally, ResMed's balance sheet remains fortress-like, with negligible debt and substantial net cash. The company continues to return capital aggressively, repurchasing $175 million of shares in the most recent quarter alone. A recently announced agreement to sell its MatrixCare software business for $490 million will further sharpen the focus on core sleep and breathing health while providing additional capital for buybacks at depressed share prices.
The bear case centers on two overlapping threats. First, Philips — sidelined from the U.S. flow generator market since its massive 2021 recall — appears to be preparing a return. Stifel's due diligence noted increased activity at Philips' key supplier, suggesting a potential market re-entry in late 2026. Survey data collected by the firm indicates ResMed's device market share could contract by roughly 1,000 basis points once Philips resumes selling.
Second, a growing number of Wall Street firms have turned cautious. Morgan Stanley downgraded RMD to Equal Weight in June 2026, cutting its price target from $286 to $230. Citigroup followed with a downgrade to Neutral in July, citing earnings growth concerns tied to component scarcity in the Astral portable ventilator line. RBC Capital also moved to the sidelines. While the overall consensus remains a Moderate Buy, the trend of downward revisions cannot be ignored.
Beyond company-specific issues, the broader healthcare sector has faced a sharp selloff, partly driven by tariff-related uncertainty and rotation away from defensive names. ResMed shares, with a forward P/E (price-to-earnings) ratio now around 16–17 times — the lowest in over a decade — reflect genuine market anxiety rather than any fundamental breakdown in the business.
From a technical perspective, RMD has established a support zone between $180 and $195, an area that held during multiple tests in recent months. The 50-day moving average sits near $201, while the 200-day moving average around $229 represents the first significant overhead resistance. A sustained move above the 200-day would confirm a trend shift and open the door toward the $250 target. Until that happens, the stock remains in a technically damaged position after its prolonged decline from the August 2025 peak.
Among 16 to 18 analysts covering ResMed, the average twelve-month price target ranges from approximately $248 to $267, with individual estimates spanning from $180 on the low end to $345 on the high end. UBS maintains the most bullish stance with a $345 target, while firms such as Goldman Sachs and KeyBanc retain Buy ratings with targets between $266 and $299. The consensus implies that a move to $250 is not only possible but represents the base-case expectation of sell-side research — assuming the company navigates the Philips re-entry and GLP-1 headwinds without a material deterioration in fundamentals.
Navigating a stock like ResMed — where the long-term growth thesis competes with near-term sentiment shocks — requires staying alert to changing market conditions. Tickeron's AI Daily Buy/Sell Signals continuously monitor thousands of stocks and ETFs, using artificial intelligence to generate Buy, Sell, or Hold signals based on evolving technical patterns, market behavior, and AI-driven analysis. Traders can use these signals to identify emerging opportunities, monitor existing positions more efficiently, and spot shifts in market trends before they become obvious. For those tracking whether RMD can regain momentum toward $250, AI-powered signal tools offer a data-driven way to stay ahead of the curve.
A return to $250 appears achievable for ResMed but is far from guaranteed. The bullish case rests on a genuinely underpenetrated global market, expanding margins, a pristine balance sheet, and real-world data suggesting GLP-1 drugs may complement rather than cannibalize CPAP demand. The stock's deeply discounted valuation also means that even modest positive catalysts could trigger a significant re-rating.
However, the obstacles are equally real. Philips' return to the U.S. market, component shortages affecting key product lines, and a recent wave of analyst downgrades create genuine uncertainty. The stock's technical picture remains weak below the 200-day moving average, and broader sector rotation away from healthcare could keep a lid on any rally.
Investors should monitor upcoming earnings — with full-year fiscal 2026 results due in early August 2026 — for evidence that the core sleep apnea franchise can sustain double-digit growth in the face of these headwinds. Also worth watching: any concrete developments around the Philips re-entry timeline, the integration of the newly acquired Noctrix wearable technology, and the deployment of capital from the MatrixCare divestiture. The path to $250 exists, but it will almost certainly require patience and a steady stream of reassuring operational data.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, RMD has been loosely correlated with COO. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if RMD jumps, then COO could also see price increases.
| Ticker / NAME | Correlation To RMD | 1D Price Change % | ||
|---|---|---|---|---|
| RMD | 100% | -1.01% | ||
| COO - RMD | 50% Loosely correlated | -0.56% | ||
| BAX - RMD | 47% Loosely correlated | -1.18% | ||
| SOLV - RMD | 46% Loosely correlated | +2.46% | ||
| BDX - RMD | 46% Loosely correlated | +0.79% | ||
| ISRG - RMD | 43% Loosely correlated | -1.68% | ||
More | ||||
| Ticker / NAME | Correlation To RMD | 1D Price Change % |
|---|---|---|
| RMD | 100% | -1.01% |
| Pharmaceuticals: Other industry (52 stocks) | 40% Loosely correlated | +0.03% |
| Pharmaceuticals industry (157 stocks) | -0% Poorly correlated | +0.64% |